title: Diabetic neuropathy and zinc therapy.
abstract: This was a double blind study conducted on 60 subjects; 20 age and sex matched healthy controls (Group-I), 20 patients of diabetes mellitus with neuropathy who received placebo for 6 weeks (Group-IIA); and 20 patients of diabetes mellitus with neuropathy who were given oral 660 mg zinc sulphate for 6 weeks (Group-IIB). Serum zinc level, fasting blood sugar (FBS), blood sugar 2 hour after breakfast (2HABF) and motor nerve conduction velocity (MNCV) were estimated on day 0 and after 6 weeks in all subjects. Serum zinc levels were significantly low (p<0.001) in group II-A and II-B as compared to healthy controls (group-I) at base line. After 6 weeks the changes in pre and post therapy values of FBS, 2HABF and MNCV (median and common peroneal nerve) were highly significant (p<0.001) for group II-B alone with insignificant change (p>0.05) in group II-A. Therefore, zinc therapy helps in achieving better glycemic control and improvement in peripheral neuropathy as assessed by MNCV.
authors.affiliation: Deptt. of Neuromedicine, SSMC, Dhaka.
authors.forename: M A
authors.initials: MA
authors.lastname: Hayee
authors.forename: Q D
authors.initials: QD
authors.lastname: Mohammad
authors.forename: A
authors.initials: A
authors.lastname: Haque
mesh_terms: D000328:Adult; D001252:Astringents / Q000008:administration & dosage / Q000627:therapeutic use*; D001459:Bangladesh; D003929:Diabetic Neuropathies / Q000628:therapy*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010919:Placebos; D019287:Zinc Sulfate / Q000008:administration & dosage / Q000627:therapeutic use*
chemical_list: D001252:Astringents; D010919:Placebos; D019287:Zinc Sulfate